Pfizer Doesn’t Like Crossover Design For Placebo Patients In COVID-19 Vaccine Trial

 
• By Derrick Gingery
  
A crossover design could allow for more long-term safety and efficacy follow-up.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers